- BMY stock up 35% since Barron's recommendation one year ago.
Bristol Myers Squibb reported Q3 revenue of $13.1 billion, up 7%, and raised full-year guidance. The stock trades at 10x forward earnings with a 4.1% dividend yield and multiple pipeline catalysts ahead.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.